Naronapride

Naronapride was conceived as a structurally optimized descendant of cisapride, engineered to keep the potent 5-HT4 prokinetic action while removing the two features that made cisapride dangerous: QT-prolonging cardiac activity and reliance on cytochrome P450 metabolism that produced drug interactions ^[1]. It is grouped with prucalopride and velusetrag among the highly selective, high-affinity 5-HT4 agonists that define the modern prokinetic class ^[2].

In a randomized, double-blind, placebo-controlled study in healthy volunteers, nine days of naronapride at 3, 10, or 20 mg three times daily accelerated overall colonic transit, tended to speed gastric emptying and ascending-colon emptying, and loosened stool consistency, with the mid-range doses generally most effective and no safety signals detected ^[1]. These pharmacodynamic effects establish it as an active, orally effective prokinetic across the gut.

A meta-analysis of highly selective 5-HT4 agonists in chronic constipation included naronapride alongside prucalopride and velusetrag and found the class superior to placebo for spontaneous bowel movements and constipation-related quality of life, with generally minor adverse events dominated by headache ^[2]. Reviews of investigational prokinetics have repeatedly highlighted naronapride, together with velusetrag and YKP10811, as the 5-HT4 agonists most likely to advance on the basis of efficiency and cardiac safety ^[3].

In healthy-volunteer pharmacodynamic studies naronapride produced no identified safety issues, and the expected effects were those of increased motility such as looser stools and, at higher doses, diarrhea. Because it neither blocks the hERG channel appreciably nor depends on cytochrome P450 metabolism, it was intended to avoid both the cardiac arrhythmia risk and the drug-interaction burden that led to cisapride's withdrawal. As an investigational compound, its long-term safety in patient populations and at scale remains to be fully established.

Naronapride was developed under the code ATI-7505 by Aryx Therapeutics using a design strategy explicitly aimed at recreating cisapride's efficacy while engineering out its cardiac and metabolic liabilities. Early human pharmacodynamic work at the Mayo Clinic in the mid-2000s demonstrated dose-dependent acceleration of gastrointestinal and colonic transit. It subsequently entered development for chronic constipation and gastroparesis and became a standard member of the highly selective 5-HT4 agonist class in the constipation and dysmotility literature.

Naronapride is well regarded in gastroenterology as a rationally designed, cardiac-safe cisapride successor and is routinely included in meta-analyses and reviews of highly selective 5-HT4 agonists. It is discussed as a promising investigational prokinetic rather than an established therapy, since it has not reached broad approval. It has essentially no nootropic profile because it was optimized for peripheral gastrointestinal activity.